Compare GE Aerospace (GE) vs Spyre Therapeutics Inc. Common Stock (SYRE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GE Aerospace vs Spyre Therapeutics Inc. Common Stock — how do they compare? GE Aerospace trades at $307.62 (market cap $319.19B), while Spyre Therapeutics Inc. Common Stock trades at $78.63 (market cap $7.52B). The key difference: GE Aerospace is far larger — about 42.4× Spyre Therapeutics Inc. Common Stock's market cap, and GE Aerospace pays a 0.61% dividend while Spyre Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold GE Aerospace for 111 Days and Spyre Therapeutics Inc. Common Stock for 0 Days on average.
| GE | SYRE | |
|---|---|---|
Market Cap | $319.19B | $7.52B |
Volume | 4,516,693 | 1,441,031 |
Sector | Industrials | Health |
52-Week High | $381.22 | $108.92 |
52-Week Low | $273.25 | $22.18 |
Typical Hold Time | 111 Days | 0 Days |
Enterprise Value | $329.00B | $6.52B |
Dividend Yield | 0.61% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GE Aerospace trades at $308.64, showing modest daily gains of 0.14% amid mixed technical signals. The stock maintains strong fundamentals with three consecutive quarterly earnings beats, robust 48.79% ROE, and improving profit margins reaching 18.98% in 2025. Recent news highlights the company's $12 billion CPP acquisition to strengthen its aerospace supply chain capabilities while maintaining shareholder returns through dividends and buybacks.
Outlook remains positive with analyst consensus at $409.60 price target (32.7% upside) and no sell ratings. Key opportunities include aerospace demand growth and strategic acquisitions, while risks involve high valuation multiples (P/E 36.28) and integration challenges from recent M&A activity. The bearish technical picture suggests potential near-term consolidation before fundamental strengths drive long-term appreciation.
SYRE trades at $80.45, down 6.34% over 24 hours, with technical indicators showing neutral momentum near key support at $79. The clinical-stage biotech shows no revenue but maintains strong analyst support (92% buy rating) with a $119.89 consensus target. Recent positive SPY003 phase II ulcerative colitis data (Zacks, 2026-09-09) and a $350 million public offering (GlobeNewsWire, 2026-10-05) provide catalysts, though financials reflect pre-revenue challenges with a -197.71% net margin.
Investment outlook balances high-risk, high-reward potential. The robust pipeline in inflammatory bowel disease offers substantial upside if clinical successes continue, but the absence of revenue, negative cash flow from operations, and reliance on financing pose significant risks. Near-term price action will hinge on Q3 2026 earnings and further clinical updates.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About GE Aerospace
General Electric Company is a globally diversified technology and financial services company. The Company's products and services include aircraft engines, power generation, water processing, and household appliances to medical imaging, business and consumer financing, and industrial products.
Read more on GE →About Spyre Therapeutics Inc. Common Stock
Spyre Therapeutics develops extended half-life antibody therapies for inflammatory bowel disease, including ulcerative colitis and Crohn's disease. Its pipeline targets pathways such as α4β7, TL1A, and IL-23 with antibodies engineered for infrequent subcutaneous dosing and potential combination use.
Read more on SYRE →
